Copyright © 2021. Inderes Oyj. All rights reserved.

Nexstim

Viimeisimmät raportit

Laaja raportti

Analyytikko

Antti Siltanen

Antti Siltanen

Analyytikko

Lisätiedot

Viimeisin video

Sisäpiirin kaupat

Nettovaikuttavuus

Muut analyysit
1.3.
2022

Redeye is encouraged by the continued momentum in Nexstim and path towards profitability, although with a somewhat new focus following the recent licensing agreement.

Muut analyysit
28.2.
2022

We given an initial take on Nexstim’s H2 report, that further proved Nexstim’s capability to turn the company profitable.

Muut analyysit
15.2.
2022

Redeye is cautiously optimistic to yesterday’s licensing agreement between Nexstim and Magnus Medical and gives an initial take.

Muut analyysit
16.12.
2021

We give a short comment on the results from Nexstim’s pilot study in chronic pain.

Muut analyysit
15.12.
2021

Since our initiation of coverage, Nexstim has continued to deliver solid and higher-than-expected growth in its key segments of diagnostics and therapeutics.

Muut analyysit
22.10.
2021

Redeye has a positive take on the news that Nexstim has launched a combined NBS/NBT system in the US. We give a short comment.

Muut analyysit
13.8.
2021

We give our take on today’s H1 report from Nexstim. We are overall pleased with the developments in Nexstim so far this year, as sales exceeded our estimates with significant growth across the board.

Muut analyysit
2.7.
2021

Nexstim announced today that its ongoing pilot study using an accelerated TMS protocol to treat chronic neuropathic pain has been slightly delayed due to the pandemic. The company will continue to recruit patients during Q3 (previously H1).

Nexstim

ipo 

Inderes kategoriat

Inderes Yhtiöasiakas